Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

@article{Orlowski2002PhaseIT,
  title={Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.},
  author={Robert Z. Orlowski and Thomas E. Stinchcombe and Beverly S. Mitchell and Thomas Charles Shea and Albert S Baldwin and Stephanie Stahl and Julian Adams and D E Esseltine and Peter J. Elliott and Christine S Pien and Roberto Guerciolini and Jessica K Anderson and Natalie D Depcik-Smith and Rita Bhagat and Mary Jo Lehman and Steven C. Novick and Owen A O'connor and Steven L. Soignet},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 22},
  pages={4420-7}
}
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacodynamics (PD) of the proteasome inhibitor bortezomib (previously known as PS-341) in patients with refractory hematologic malignancies. PATIENTS AND METHODS Patients received PS-341 twice weekly for 4 weeks at either 0.40, 1.04, 1.20, or 1.38 mg/m(2), followed by a 2-week rest. The PD of PS-341 was evaluated by measurement of whole blood 20S proteasome activity. RESULTS Twenty-seven patients… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 222 extracted citations

Similar Papers

Loading similar papers…